CurifyLabs, a Helsinki-based healthtech company focused on automated compounding for personalized medicines, has raised $14 million in a Series A round co-led by Sandwater and HealthCap.
The round also included Tesi, Finnish Industry Investment Ltd, existing investor Lifeline Ventures, and participation from U.S. customers and employees.
CurifyLabs develops automated compounding systems used by pharmacies and hospitals to produce personalized medicines. The company says its platform is already in use at pharmacies in 21 U.S. states and across Europe.
According to CurifyLabs, the new funding will be used to expand its U.S. operations, strengthen its supply chain, improve customer support, and accelerate product innovation.
The raise comes as healthcare providers and pharmacies look for more efficient ways to deliver patient-specific treatments, an area where automation and quality control are drawing increasing investor attention.
The round also included Tesi, Finnish Industry Investment Ltd, existing investor Lifeline Ventures, and participation from U.S. customers and employees.
CurifyLabs develops automated compounding systems used by pharmacies and hospitals to produce personalized medicines. The company says its platform is already in use at pharmacies in 21 U.S. states and across Europe.
According to CurifyLabs, the new funding will be used to expand its U.S. operations, strengthen its supply chain, improve customer support, and accelerate product innovation.
The raise comes as healthcare providers and pharmacies look for more efficient ways to deliver patient-specific treatments, an area where automation and quality control are drawing increasing investor attention.